These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 34183428)

  • 1. Circulating Thrombospondin-2 as a Novel Fibrosis Biomarker of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes.
    Lee CH; Seto WK; Lui DT; Fong CH; Wan HY; Cheung CY; Chow WS; Woo YC; Yuen MF; Xu A; Lam KS
    Diabetes Care; 2021 Sep; 44(9):2089-2097. PubMed ID: 34183428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum thrombospondin-2 level changes with liver stiffness improvement in patients with type 2 diabetes.
    Mak JHC; Lui DT; Fong CH; Cheung CY; Wong Y; Lee AC; Hoo RL; Xu A; Tan KC; Lam KS; Lee CH
    Clin Endocrinol (Oxf); 2024 Mar; 100(3):230-237. PubMed ID: 38127469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum thrombospondin 2 is a novel predictor for the severity in the patients with NAFLD.
    Kimura T; Tanaka N; Fujimori N; Yamazaki T; Katsuyama T; Iwashita Y; Pham J; Joshita S; Pydi SP; Umemura T
    Liver Int; 2021 Mar; 41(3):505-514. PubMed ID: 33386676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombospondin 2 is a key determinant of fibrogenesis in non-alcoholic fatty liver disease.
    Kimura T; Iwadare T; Wakabayashi SI; Kuldeep S; Nakajima T; Yamazaki T; Aomura D; Zafar H; Iwaya M; Joshita S; Uehara T; Pydi SP; Tanaka N; Umemura T
    Liver Int; 2024 Feb; 44(2):483-496. PubMed ID: 38010940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive Role of Neutrophil-Percentage-to-Albumin Ratio (NPAR) in Nonalcoholic Fatty Liver Disease and Advanced Liver Fibrosis in Nondiabetic US Adults: Evidence from NHANES 2017-2018.
    Liu CF; Chien LW
    Nutrients; 2023 Apr; 15(8):. PubMed ID: 37111111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes.
    Ciardullo S; Perseghin G
    Metabolism; 2021 Aug; 121():154752. PubMed ID: 33716004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
    Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver Fibrosis.
    Kozumi K; Kodama T; Murai H; Sakane S; Govaere O; Cockell S; Motooka D; Kakita N; Yamada Y; Kondo Y; Tahata Y; Yamada R; Hikita H; Sakamori R; Kamada Y; Daly AK; Anstee QM; Tatsumi T; Morii E; Takehara T
    Hepatology; 2021 Nov; 74(5):2452-2466. PubMed ID: 34105780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography - a prospective, cross sectional study.
    Mikolasevic I; Domislovic V; Turk Wensveen T; Delija B; Klapan M; Juric T; Lukic A; Mijic A; Skenderevic N; Puz P; Ostojic A; Krznaric Z; Radic-Kristo D; Filipec Kanizaj T; Stimac D
    Eur J Intern Med; 2020 Dec; 82():68-75. PubMed ID: 32839076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis.
    Sagara M; Iijima T; Kase M; Kato K; Sakurai S; Tomaru T; Jojima T; Usui I; Aso Y
    J Diabetes Complications; 2021 May; 35(5):107885. PubMed ID: 33602617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic accuracy of combined biomarker measurements and vibration-controlled transient elastography (VCTE) for predicting fibrosis stage of non-alcoholic fatty liver disease.
    Shima T; Sakai K; Oya H; Katayama T; Mitsumoto Y; Mizuno M; Kanbara Y; Okanoue T
    J Gastroenterol; 2020 Jan; 55(1):100-112. PubMed ID: 31538241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of patients with type 2 diabetes with non-alcoholic fatty liver disease who are at increased risk of progressing to advanced fibrosis: a cross-sectional study.
    Mettananda C; Egodage T; Dantanarayana C; Fernando R; Ranaweera L; Luke N; Ranawaka C; Kottahachchi D; Pathmeswaran A; de Silva HJ; Dassanayake AS
    BMJ Open; 2023 Jan; 13(1):e063959. PubMed ID: 36639212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.
    Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S
    Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease.
    Lee HW; Kim BK; Kim SU; Park JY; Kim DY; Ahn SH; Kim KJ; Han KH
    Dig Dis Sci; 2017 Aug; 62(8):2150-2158. PubMed ID: 28523578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating thrombospondin 2 levels reflect fibrosis severity and disease activity in HCV-infected patients.
    Iwadare T; Kimura T; Tanaka N; Yamazaki T; Wakabayashi SI; Okumura T; Kobayashi H; Yamashita Y; Pydi SP; Nakajima T; Iwaya M; Sugiura A; Joshita S; Uehara T; Umemura T
    Sci Rep; 2022 Nov; 12(1):18900. PubMed ID: 36344733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
    Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis of liver fibrosis in ageing patients with HIV at risk for non-alcoholic fatty liver disease in Italy and Canada: assessment of a two-tier pathway.
    Sebastiani G; Milic J; Gioe C; Al Hinai AS; Cervo A; Lebouche B; Deschenes M; Cascio A; Mazzola G; Guaraldi G
    Lancet HIV; 2022 Mar; 9 Suppl 1():S4. PubMed ID: 35304846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing aortic stiffness is predictive of advanced liver fibrosis in patients with type 2 diabetes: the Rio-T2DM cohort study.
    Leite NC; Villela-Nogueira CA; Ferreira MT; Cardoso CR; Salles GF
    Liver Int; 2016 Jul; 36(7):977-85. PubMed ID: 26509555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
    Lai LL; Wan Yusoff WNI; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1396-1403. PubMed ID: 30551263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B.
    Mak LY; Hui RW; Fung J; Liu F; Wong DK; Cheung KS; Yuen MF; Seto WK
    J Hepatol; 2020 Oct; 73(4):800-806. PubMed ID: 32504663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.